A maker of computer software that lets pharmaceutical companies test drugs "on screen" before they ever reach a lab or a patient. Its tools—like GastroPlus, ADMET Predictor, and DILIsym—predict how a compound moves through the body and whether it might harm the liver, and its services help with modeling and clinical trial training. Founder Walt Woltosz started the company in 1996 after bringing aerospace-style simulation ideas into drug development. Its name simply joins "simulations" with a "plus," a nod to the extra technology baked in.
Simulations Plus announces expiration of HSR waiting period for Altaris acquisition
The merger agreement was entered into on June 16, 2026, with SP Evolution HoldCo II, LLC as parent and SP Evolution BidCo II, LLC as merger sub.
Show detailsHide details
The Hart-Scott-Rodino waiting period for the pending acquisition of Simulations Plus by Altaris, LLC has expired, satisfying one regulatory condition for the merger.
The transaction remains subject to shareholder approval and certain regulatory approvals in France.
The closing is currently expected in the second half of calendar 2026, subject to remaining conditions.
A press release announcing the HSR expiration was filed as Exhibit 99.1.
8.01 Other Events · 9.01 Financial Statements and Exhibits
Simulations Plus reports Q3 FY2026 revenue up 7% to $21.9M, net income $3.6M
Total revenue for Q3 FY2026 (ended May 31, 2026) increased 7% to $21.9 million, with services revenue up 20% to $9.3 million and software revenue flat at $12.6 million.
Show detailsHide details
Gross profit was $15.1 million (69% margin) versus $13.0 million (64%) in the prior-year quarter; net income was $3.6 million ($0.18 diluted EPS) versus a net loss of $67.3 million ($3.35 loss per share).
Adjusted EBITDA for Q3 was $7.9 million (36% of revenue), compared to $7.4 million (37%) a year ago; adjusted net income was $6.1 million ($0.30 adjusted diluted EPS) versus $9.0 million ($0.45).
For the nine months ended May 31, 2026, total revenue rose 5% to $64.6 million, with net income of $8.8 million ($0.43 diluted EPS) versus a net loss of $64.0 million in the prior-year period.
On June 15, 2026, the company entered into a definitive merger agreement to be acquired by affiliates of Altaris, LLC, with closing expected in the fourth quarter of calendar 2026.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Simulations Plus to be acquired by Altaris affiliate for $18.50 per share in cash
Simulations Plus entered into a merger agreement with SP Evolution BidCo II, LLC, an affiliate of Altaris, LLC, on June 15, 2026.
Show detailsHide details
Each share of Simulations Plus common stock will be converted into the right to receive $18.50 in cash, without interest.
The merger is subject to shareholder approval, regulatory approvals, and other customary closing conditions; it is not subject to a financing condition.
The Woltosz Shareholders, owning approximately 16% of outstanding shares, have agreed to vote in favor of the merger.
The merger agreement includes termination fees: $26 million payable by Parent in certain circumstances and $13 million payable by the Company in others.
1.01 Entry into a Material Definitive Agreement · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Simulations Plus to be acquired by Altaris affiliates for $375M, $18.50/share cash
Simulations Plus, Inc. entered into a definitive merger agreement with affiliates of Altaris, LLC, an investment firm focused on healthcare.
Show detailsHide details
Stockholders will receive $18.50 per share in cash, a 26% premium to the 60-day volume-weighted average price as of June 15, 2026.
The transaction is valued at approximately $375 million and is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals.
At closing, Simulations Plus is expected to be combined with Chemical Computing Group, an existing Altaris portfolio company.
The merger agreement was unanimously approved by Simulations Plus's Board; cofounder Dr. Walter Woltosz agreed to vote his shares in favor.
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Simulations Plus reports Q2 FY2026 revenue up 8% to $24.3M, net income $4.5M
Total revenue increased 8% to $24.3 million for the second quarter ended February 28, 2026, compared to the same period last year.
Show detailsHide details
Software revenue grew 9% to $14.6 million (60% of total revenue); services revenue grew 8% to $9.7 million (40% of total revenue).
Gross profit was $16.1 million with gross margin of 66%, up from $13.1 million and 59% in the prior year quarter.
Net income was $4.5 million and diluted EPS was $0.22, compared to $3.1 million and $0.15 in the prior year quarter.
The company lowered its fiscal 2026 adjusted diluted EPS guidance to $0.75-$0.85 from $1.03-$1.10, citing an increased expected effective tax rate of 23-25%.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Simulations Plus shareholders approve 2021 Equity Incentive Plan amendment increasing authorized shares to 3.45 million.
The Plan Amendment was previously approved by the Board on December 23, 2025 and became effective on February 12, 2026.
Show detailsHide details
At the February 12, 2026 Annual Meeting, shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing authorized shares from 2,500,000 to 3,450,000.
Four directors were elected: Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia, and Sharlene Evans, each to serve until the next annual meeting.
Shareholders ratified the appointment of Rose, Snyder & Jacobs LLP as the independent registered public accounting firm for fiscal year ending August 31, 2026.
On a non-binding advisory vote, shareholders favored a 1-year frequency for future say-on-pay votes.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Simulations Plus enters amended employment agreements with CEO and six other executives
On December 2, 2025, Simulations Plus entered into amended/restated employment agreements with CEO Shawn O'Connor, CFO Will Frederick, CRO John DiBella, and President Service Solutions Jill Fiedler-Kelly, and initial agreements with Co-Chief Product & Technology Officer Erik Guffrey, COO Josh Fohey, and Chief Scientific Officer Viera Lukacova.
Show detailsHide details
CEO O'Connor receives an annual base salary of $547,700, a target cash bonus of 75% of base salary, and a target stock option grant of 50,000 options under the 2021 Equity Incentive Plan.
CFO Frederick receives a base salary of $359,100, target cash bonus of 35% of base, and 20,000 target options; CRO DiBella receives $359,100 base, 25% target cash bonus, and 15,000 target options.
Fiedler-Kelly, Guffrey, Fohey, and Lukacova each receive base salaries of $334,700, $300,600, $283,100, and $318,700 respectively, with 25% target cash bonuses and 15,000 target options each.
All agreements are effective December 2, 2025, and provide for twelve months' base salary and COBRA benefits upon termination without Cause, subject to signing a release.
1.01 Entry into a Material Definitive Agreement · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits